Novartis
-
Novartis: Ianalumab Phase III Trials Achieve Primary Endpoint in Sjögren’s Disease Patients
Novartis announced positive top-line results from Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) evaluating ianalumab (VAY736) in Sjögren’s disease. Both trials met the primary endpoint, showing statistically significant reduction in disease activity. Ianalumab, with its dual mechanism, is poised to potentially be the first targeted treatment for this autoimmune condition. The drug demonstrated a favorable safety profile and will be submitted to global health authorities.
